Bayer shares surge 10% after major legal victory in Roundup cancer litigation: Time to buy?

Bayer AG saw its shares soar by 10% in early German trading following a crucial legal victory concerning its Roundup weedkiller.

The surge came after a Philadelphia appeals court ruled in favor of Bayer’s Monsanto unit, overturning a previous decision that had found the company liable for cancer risks associated with the herbicide.

This ruling marks a significant win for Bayer, offering potential relief in its ongoing legal battles and providing a boost to its embattled stock.

Bayer’s stock had declined nearly 49%

The appeals court’s decision centered on the interpretation of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), a federal regulation that requires uniform labeling of pesticides across the US.

The court determined that federal law preempts state law claims, thereby negating the previous ruling against Bayer.

This legal victory could have far-reaching implications for Bayer, especially in state courts where most Roundup-related cases are being heard.

The ruling may set a precedent that could influence the outcomes of ongoing and future litigation against the company.

Bayer’s stock, which had suffered a dramatic decline of nearly 49% over the past year, rebounded sharply by 10% in intraday trading on Friday.

This marks the largest intraday gain for the company in five years and offers a glimmer of hope to investors who have seen Bayer’s stock price plunge by more than 70% since its controversial acquisition of Monsanto in 2018.

The decision might be reviewed by the top court

The ruling has significant implications for the numerous lawsuits Bayer faces over Roundup.

The case that led to this decision involved a professional landscaper who claimed that exposure to Roundup caused his non-Hodgkin’s lymphoma.

The appeals court overturned the prior verdict that had favored the plaintiff, asserting that Monsanto was not required to warn users of the alleged cancer risks under Pennsylvania law due to federal preemption.

This ruling suggests that state law claims may not prevail if they conflict with federal regulations, a development that could deter future lawsuits against Bayer.

The company has reported that 114,000 of the 172,000 lawsuits filed over Roundup have been resolved or dismissed.

However, Bayer also noted that the decision could still be reviewed by the US Supreme Court, potentially opening the door to further legal challenges.

Bayer’s shares gain momentum

The market responded positively to the court ruling, with Bayer’s shares gaining momentum on the Frankfurt Stock Exchange.

By 11:15 a.m., the stock was up over 8%, significantly outperforming the DAX, which saw a modest rise of around 0.5% during the same period.

The sharp increase in Bayer’s share price reflects investor optimism that the company might be able to mitigate some of the financial risks tied to the Roundup litigation.

While this court ruling is a favorable development for Bayer, the company remains entangled in numerous legal battles over Roundup.

The potential review by the US Supreme Court could either solidify this victory or reignite legal uncertainties.

For now, Bayer’s shareholders have reason to be cautiously optimistic as the company navigates its complex legal landscape.

The post Bayer shares surge 10% after major legal victory in Roundup cancer litigation: Time to buy? appeared first on Invezz